AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18634944 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 22
Study 15623360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendo‐Achilles lengthening (TAL)
Number of subjects: 29
Study 15623360 — intervention group
Group type: COMPARATOR
Intervention: Total‐contact casting (TCC)
Number of subjects: 29
Study 12047483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg single dose on day 1 followed by 62.5 mg twice daily for 5.5 days
Number of subjects: 10
Study 12047483 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 5.5 days plus ketoconazole 200 mg once daily for 6 days
Number of subjects: 10
Study 12047483 — intervention group
Group type: COMPARATOR
Intervention: Control group (Bosentan only)
Number of subjects: 10
Study 10068176 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg OTFC
Number of subjects: 74
Study 10068176 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg OTFC
Number of subjects: 74
Study 10068176 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC (various doses: 200, 400, 600, 800, 1200, 1600 microg)
Number of subjects: 74
Study 10068176 — intervention group
Group type: EXPERIMENTAL
Intervention: OTFC
Number of subjects: 74
Study 10068176 — intervention group
Group type: COMPARATOR
Intervention: Usual rescue drug
Number of subjects: 74
Study 7783098 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension (ISH) defined as SBP >= 160 mmHg and DBP < 90 mmHg
Number of subjects: 6621
Study 7783098 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension (ISH)
Number of subjects: 6621
Study 1792612 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 419
Study 1792612 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PP)
Number of subjects: 419
Study 1792612 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (PS)
Number of subjects: 419
Study 1792612 — intervention group
Group type: COMPARATOR
Intervention: Diuretic
Number of subjects: 419
Study 1792612 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 419
Study 6362559 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 88
Study 6362559 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 88
Study 31278011 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory training during the postoperative period
Number of subjects: 34
Study 31278011 — intervention group
Group type: COMPARATOR
Intervention: Active control group engaging in alternative activities
Number of subjects: 34
Study 29566379 — intervention group
Group type: EXPERIMENTAL
Intervention: Apabetalone 100mg twice-daily for 24 and 26 weeks
Number of subjects: 48
Study 29566379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 26914983 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART criteria
Number of subjects: 251
Study 26914983 — intervention group
Group type: COMPARATOR
Intervention: WHO criteria
Number of subjects: 251
Study 26914983 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 251
Study 25371578 — intervention group
Group type: EXPERIMENTAL
Intervention: Connective Tissue Mobilization (CTM)
Number of subjects: 100
Study 25371578 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 22496334 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion carotid endarterectomy (CEA)
Number of subjects: 563
Study 22496334 — intervention group
Group type: COMPARATOR
Intervention: Conventional carotid endarterectomy (CEA)
Number of subjects: 563
Study 20347259 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediational Intervention for Sensitizing Caregivers (MISC)
Number of subjects: 19
Study 20347259 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 18628419 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE 0.625 mg alone
Number of subjects: 428
Study 18628419 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + daily medroxyprogesterone acetate (MPA) 2.5 mg
Number of subjects: 428
Study 18628419 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + cyclical MPA (10 mg days 1‐12 per 28‐day cycle)
Number of subjects: 428
Study 18628419 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + cyclical micronized progesterone (10 mg days 1‐12)
Number of subjects: 428
Study 16266650 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (four 45-minute training sessions over 2 months)
Number of subjects: 376
Study 16266650 — intervention group
Group type: COMPARATOR
Intervention: Control group (only received feedback and bulletins)
Number of subjects: 376
Study 12244891 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 mg/die Egb 761 (group I = 50 patients)
Number of subjects: 99
Study 12244891 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/die Egb 761 (group II = 49 patients)
Number of subjects: 99
Study 10071708 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 526
Study 10071708 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 526
Study 7741412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacemaker implantation (PMG)
Number of subjects: 450
Study 7741412 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 450
Study 1828266 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine
Number of subjects: 52
Study 1828266 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 394275 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltarol)
Number of subjects: 109
Study 394275 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 109
Study 394275 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Diclofenac and Indomethacin)
Number of subjects: 109
Study 31625535 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Engagement (WE)
Number of subjects: 100
Study 31625535 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiding Feelings (HF)
Number of subjects: 100
Study 31625535 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Engagement (WE) with Hiding Feelings (HF)
Number of subjects: 100
Study 26559707 — intervention group
Group type: EXPERIMENTAL
Intervention: Nut-based snack bars (NBSB)
Number of subjects: 34
Study 26559707 — intervention group
Group type: COMPARATOR
Intervention: Conventional snack foods
Number of subjects: 34
Study 26359580 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous scanning technique
Number of subjects: 0
Study 26359580 — intervention group
Group type: COMPARATOR
Intervention: Sequential scanning technique
Number of subjects: 0
Study 26359580 — intervention group
Group type: EXPERIMENTAL
Intervention: Phantom evaluation
Number of subjects: 0
Study 22451113 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 1527
Study 22451113 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer data
Number of subjects: 1527
Study 23115402 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 15 mg plus extended-release topiramate 92 mg
Number of subjects: 45
Study 23115402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 20216464 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (20 mg kg(‐1) i.v.)
Number of subjects: 12
Study 20216464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17977294 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc lactate (n = 16)
Number of subjects: 59
Study 17977294 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride-stannous fluoride (n = 13)
Number of subjects: 59
Study 17977294 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan (n = 15)
Number of subjects: 59
Study 17977294 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial agent (control; n = 15)
Number of subjects: 59
Study 15743361 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg IV bolus, n = 22)
Number of subjects: 80
Study 15743361 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of somatostatin (500 microg/h, n = 20)
Number of subjects: 80
Study 15743361 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 7)
Number of subjects: 80
Study 11666118 — intervention group
Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA), 60 mg, oral tablets, thrice daily for 12 months
Number of subjects: 0
Study 11666118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11666118 — intervention group
Group type: EXPERIMENTAL
Intervention: Total triterpenic fraction of Centella asiatica (TTFCA)
Number of subjects: 0
Study 11666118 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 9638783 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant Psychological Therapy (APT)
Number of subjects: 57
Study 9638783 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling
Number of subjects: 57
Study 8037558 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent antegrade warm blood cardioplegia
Number of subjects: 200
Study 8037558 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 200
Study 3290413 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg/dose twice daily for 2 weeks)
Number of subjects: 70
Study 3290413 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 2 weeks)
Number of subjects: 70
Study 3290413 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 70
Study 29635503 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller portion size of food
Number of subjects: 0
Study 29635503 — intervention group
Group type: COMPARATOR
Intervention: Larger portion size of food
Number of subjects: 0
Study 27871643 — intervention group
Group type: EXPERIMENTAL
Intervention: Reward positivity (RewP) response in children with depression
Number of subjects: 78
Study 27871643 — intervention group
Group type: COMPARATOR
Intervention: Reward positivity (RewP) response in healthy children
Number of subjects: 78
Study 24605812 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 1 mg/cm²
Number of subjects: 360
Study 24605812 — intervention group
Group type: EXPERIMENTAL
Intervention: ATX-101 2 mg/cm²
Number of subjects: 360
Study 24605812 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 22995944 — intervention group
Group type: EXPERIMENTAL
Intervention: C-QIDS-C
Number of subjects: 998
Study 22995944 — intervention group
Group type: EXPERIMENTAL
Intervention: C-QIDS-SR
Number of subjects: 998
Study 22995944 — intervention group
Group type: COMPARATOR
Intervention: HAMD
Number of subjects: 998
Study 20718225 — intervention group
Group type: EXPERIMENTAL
Intervention: Speeded condition for Session 1
Number of subjects: 72
Study 20718225 — intervention group
Group type: EXPERIMENTAL
Intervention: Complying with the 95% reliable diagnostic aid
Number of subjects: 72
Study 19080399 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d of prednisone for 7 days
Number of subjects: 130
Study 19080399 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d of prednisone for 10 days, then tapered to 15 mg/d for 4 days
Number of subjects: 130
Study 19080399 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 130
Study 15974845 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally delivered doxycycline hyclate (DHV)
Number of subjects: 0
Study 15974845 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control (VC)
Number of subjects: 0
Study 15974845 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP)
Number of subjects: 0
Study 15974845 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 12867675 — intervention group
Group type: EXPERIMENTAL
Intervention: Video intervention group
Number of subjects: 27
Study 12867675 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention group
Number of subjects: 27
Study 12867675 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 27
Study 10553827 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg midazolam
Number of subjects: 90
Study 10553827 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg midazolam
Number of subjects: 90
Study 10553827 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 90
Study 8688991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 15
Study 8688991 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 15
Study 8688991 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15
Study 8688991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1854868 — intervention group
Group type: EXPERIMENTAL
Intervention: UV light sterilization with the UV‐XD bag transfer set
Number of subjects: 51
Study 1854868 — intervention group
Group type: COMPARATOR
Intervention: Bag transfer set without UV light
Number of subjects: 51
Study 1854868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (UV light and non-UV light)
Number of subjects: 51
Study 1854868 — intervention group
Group type: EXPERIMENTAL
Intervention: UV light sterilization
Number of subjects: 51
Study 6853286 — intervention group
Group type: EXPERIMENTAL
Intervention: CVE (central vascular engorgement) via G-suit inflation
Number of subjects: 12
Study 6853286 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersion in water
Number of subjects: 12
Study 6853286 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 30003332 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycomacropeptide (GMP) 50g
Number of subjects: 15
Study 30003332 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein isolate (WPI) 50g
Number of subjects: 15
Study 30003332 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin 19 (MD19)
Number of subjects: 15
Study 30193277 — intervention group
Group type: EXPERIMENTAL
Intervention: CJR bundled payment model
Number of subjects: 130343
Study 30193277 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 130343
Study 26817718 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 25(OH)D concentration quartile 4 (Q4) compared with quartile 1 (Q1) for women with BMI < 22.4
Number of subjects: 699
Study 26817718 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 25(OH)D concentration quartile 4 (Q4) compared with quartile 1 (Q1) for women with BMI ≥ 22.4
Number of subjects: 699
Study 26817718 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma 25(OH)D concentration ≥ 10 ng/mL compared with <10 ng/mL for women with alcohol intake ≥ 7.1 g/d
Number of subjects: 699
Study 25183726 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 378
Study 25183726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 22037407 — intervention group
Group type: EXPERIMENTAL
Intervention: quetiapine (400 mg/day)
Number of subjects: 20
Study 22037407 — intervention group
Group type: COMPARATOR
Intervention: matched placebo
Number of subjects: 20
Study 20670575 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D computer-assisted navigation
Number of subjects: 42
Study 20670575 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopic control
Number of subjects: 42
Study 17765968 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 9
Study 17765968 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG
Number of subjects: 9
Study 17765968 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 9
Study 15132959 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting at the choke point
Number of subjects: 64
Study 15132959 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary stenting at migrated choke points
Number of subjects: 64
Study 11087205 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal A/C conjugate vaccination (MenA/C)
Number of subjects: 39
Study 11087205 — intervention group
Group type: EXPERIMENTAL
Intervention: Meningococcal A/C polysaccharide (MPS)
Number of subjects: 39
Study 11087205 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine (IPV)
Number of subjects: 39
Study 11087205 — intervention group
Group type: COMPARATOR
Intervention: Control group (unvaccinated age-matched subjects)
Number of subjects: 39
Study 10358462 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms s.c. every 8 hours)
Number of subjects: 21
Study 10358462 — intervention group
Group type: COMPARATOR
Intervention: Control (standard conservative treatment without octreotide)
Number of subjects: 21
Study 7641928 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct verbal instruction
Number of subjects: 104
Study 7641928 — intervention group
Group type: COMPARATOR
Intervention: Usual written instructions
Number of subjects: 104
Study 2663610 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.9 mg/24 h orally for 72 h)
Number of subjects: 19
Study 2663610 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 766572 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidoflazine (60 mg tablet t.i.d.)
Number of subjects: 14
Study 766572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 30459959 — intervention group
Group type: EXPERIMENTAL
Intervention: Group antenatal care
Number of subjects: 72
Study 30459959 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 72
Study 27723631 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Anacardium occidentale (AO)
Number of subjects: 30
Study 27723631 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine digluconate (CLX)
Number of subjects: 30
Study 27723631 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 30
Study 25073797 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC program delivered at a daycare centre only
Number of subjects: 18
Study 25073797 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC program delivered at daycare with a home/parental education component
Number of subjects: 18
Study 25073797 — intervention group
Group type: COMPARATOR
Intervention: Regular daycare curriculum
Number of subjects: 18
Study 22981021 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Care (PC)
Number of subjects: 384
Study 22981021 — intervention group
Group type: COMPARATOR
Intervention: Community Mental Health (CMH)
Number of subjects: 384
Study 20530316 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated-fractionation radiotherapy combined with cisplatin therapy
Number of subjects: 323
Study 20530316 — intervention group
Group type: COMPARATOR
Intervention: Standard-fractionation radiotherapy combined with cisplatin therapy
Number of subjects: 323
Study 20530316 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-positive tumors
Number of subjects: 323
Study 20530316 — intervention group
Group type: COMPARATOR
Intervention: HPV-negative tumors
Number of subjects: 323
Study 20530316 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco exposure
Number of subjects: 323
Study 18400703 — intervention group
Group type: EXPERIMENTAL
Intervention: High-carbohydrate diet
Number of subjects: 8
Study 15196517 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait characteristics measured in transitionally frail older adults
Number of subjects: 50
Study 15196517 — intervention group
Group type: COMPARATOR
Intervention: Comparison with published results from other older adults
Number of subjects: 50
Study 11751664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily
Number of subjects: 16
Study 11751664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 11751664 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (2‐8 pmol/min)
Number of subjects: 16
Study 11751664 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (1‐4 microg/min)
Number of subjects: 16
Study 9717790 — intervention group
Group type: EXPERIMENTAL
Intervention: measuring‐mounting catheter
Number of subjects: 10
Study 9717790 — intervention group
Group type: COMPARATOR
Intervention: visual assessment
Number of subjects: 10
Study 7714681 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen ADJ (new fortification regimen with bovine milk proteins)
Number of subjects: 12
Study 7714681 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen ADJ
Number of subjects: 12
Study 7714681 — intervention group
Group type: COMPARATOR
Intervention: Regimen FIX (conventional fixed proportion with bovine milk proteins)
Number of subjects: 12
Study 7714681 — intervention group
Group type: COMPARATOR
Intervention: Regimen FIX
Number of subjects: 12
Study 7714681 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen HMP (human milk protein-based fortifier)
Number of subjects: 12
Study 2668407 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (mean dose 67 mg/day)
Number of subjects: 58
Study 2668407 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (mean dose 329 mg/day)
Number of subjects: 58
Study 785950 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 16
Study 785950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 31006671 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (patients with type 2 diabetes mellitus)
Number of subjects: 80
Study 29111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond XT after etching with 37% phosphoric acid
Number of subjects: 150
Study 29111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC after etching with 37% phosphoric acid
Number of subjects: 150
Study 29111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC after deproteinization with 5.25% NaOCl and etching with 37% phosphoric acid
Number of subjects: 150
Study 29111130 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC after sandblasting with 50μm aluminium oxide and etching with 37% phosphoric acid
Number of subjects: 150